Today we are a great international Group

Our history started many years ago


Foundation of SORIN, a nuclear energy production center in Saluggia (Vercelli, Italy), by a JV between FIAT and Montecatini

The opening of Europe’s first in vitro diagnostics center


DiaSorin, the diagnostics division of SORIN Group, is sold to the multinational American Standard International


A management buyout brings DiaSorin ownership back to Italy


On July 19, DiaSorin is listed on the Italian stock exchange (Piazza Affari, Milan)


DiaSorin continues to grow organically and inorganically, expanding geographically and investing in technology and product innovation. It forms numerous partnerships with leading players in the global diagnostics market (Roche, Beckman Coulter, Meridian Bioscience)


DiaSorin enters the molecular diagnostics sector by acquiring the American Focus Diagnostics, now DiaSorin Molecular, adding to the Group’s competence and excellence


DiaSorin included in the FTSE MIB

DiaSorin enters a partnership with Qiagen for latent tuberculosis testing

DiaSorin acquires Siemens Healthineers’ ELISA business


DiaSorin signs an exclusive license agreement with TTP for the development of a molecular Point-of-Care (POC) solution


DiaSorin launches the LIAISON IQ analyzer with Lumos Diagnostics for POC immunodiagnostics

DiaSorin acquires the US company Luminex Corporation for $1.8bn, thus gaining multiplexing technology for molecular diagnostics and that in the Licensed Technology field

DiaSorin launches the Lyme test in partnership with QIAGEN and the MeMed BV test in partnership with MeMed


DiaSorin commercializes molecular reagent for monkeypox virus.

DiaSorin furthers its collaborations with BARDA to support clinical validation and FDA 510(k) clearance of the LIAISON® NES.

DiaSorin and B·R·A·H·M·S partnerships on a new immunodiagnostic solution to improve patient care.

Sale of Flow Cytometry business to Cytek.